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Abstract
Background: RAS genes acquire the most common somatic gain-of-function mutations in human
cancer, and almost all of these mutations are located at codons 12, 13, 61, and 146.
Methods: We present a method for detecting these K-RAS hotspot mutations in 228 cases of
colorectal cancer. The protocol is based on the multiplex amplification of exons 2, 3 and 4 in a
single tube, followed by primer extension of the PCR products using various sizes of primers to
detect base changes at codons 12, 13, 61 and 146. We compared the clinicopathological data of
colorectal cancer patients with the K-RAS mutation status.
Results: K-RAS mutation occurred in 36% (83/228) of our colorectal cancer cases. Univariate
analysis revealed a significant association between K-RAS mutation at codon 12 of exon 2 and poor
5-year survival (p = 0.023) and lymph node involvement (p = 0.048). Also, K-RAS mutation at codon
13 of exon 2 correlates with the size of the tumor (p = 0.03). Multivariate analysis adjusted for
tumor size, histologic grade, and lymph node metastasis also indicated K-RAS mutations at codon
12 and 13 of exon 2 correlate significantly with overall survival (p = 0.002 and 0.025). No
association was observed between codon 61 and 146 and clinicopathological features.
Conclusion: We demonstrated a simple and fast way to identify K-RAS mutation.
Background
The RAS genes encode a family of GTPases that act as sig-
nal switch molecules for many important cellular proc-
esses. Common in human cancers, activating ras
mutations cause the deregulation of ras protein activity,
which results in the loss of GTPase activity and the gain of
oncogenic activity [1-7]. In fact, RAS genes are the genes
that most commonly show somatic gain-of-function
mutations in human cancers [8,9]. There are three cellular
RAS genes, encoding the K-ras, H-ras and N-ras proteins,
and all show activating mutations in human tumors. Of
the three RAS  genes,  K-RAS  is the most frequently
mutated, which makes it an ideal target for cancer treat-
ment [9,10]. Meanwhile, K-RAS mutation plays an impor-
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tant role of the response rate of anti-EGFR antibodies
treatment for patients with metastatic colorectal cancer
[11,12].
RAS point mutations are highly prevalent in human can-
cers and mostly occur in codons 12, 13 and 61. These
mutations render the ras proteins insensitive to GTP-
induced hydrolysis of GTP to GDP and lock them in the
activated state [2,8,9]. Mutations in codons 10, 11, 15, 18,
19, and 22 have also been reported, but their biological
significance is unclear [13-18]. Several methods have been
developed for detecting K-RAS  mutations [19-26], but
these methods do not simultaneously recognize all base
changes at codons 12, 13 or 61 of K-RAS. Somatic mis-
sense mutation at codon 146 were found in three inde-
pendent studies of colorectal cancers from Hong Kong
and the United States, and it was suggested that these
mutations may make an equal or greater contribution to
colorectal cancer than the codon 61 mutation [27-29].
Direct sequencing of exons 2 and 3 can recognize the base
changes in codons 12, 13 and 61. But, codon 146 which
is located at exon 4, is too far apart (19,771 base pairs)
from exon 2 to be sequenced in a single reaction. In this
study, we employed a method to simultaneously detect
the base changes in codons 12, 13, 61 and 146 of K-RAS
in a single tube and establish their clinical significance in
colorectal cancer.
Results
K-RAS mutation detection assay
We designed primers adjacent to codons 12, 13, 61 and
146 of the K-RAS gene, as these are the most common
mutations in cancer. For mutation analysis of codons 12
and 13, we used different-sized primers (sense strand) to
recognize the change of the first base separately, and we
designed antisense strand primers to detect the change of
the second base of the codon to avoid interference
between primers of the same direction. We did not design
primers to detect change at the third base of codon 12 or
13 because these mutations do not result in the change of
the amino acid. For the analysis of codon 61, we designed
three different-sized primers (sense strand) to distinguish
changes in the first, second, and third bases separately.
The primers were made to be different in size either by
adding different lengths of poly(dT) tails to the 5'-end or
extending the primer sequence in order to allow for sepa-
ration based on the differences in size.
First, we analyzed codon 12 mutations using a 20mer
sense strand primer to detect the first base changes of
codon 12 and a 29mer antisense strand primer to detect
the second base changes of codon 12. To the tube with
codon 12 primers, we added two more primers to detect
the base changes at the first and second bases of codon 13
(41mer sense strand for the first base; 49mer antisense
strand for the second base). The results suggested that the
primers worked well in spite of the fact that the primers
used to detect the first or the second base changes of
codons 12 and 13 are of the same direction, suggesting
that these primers do not interfere with each other. The
extended products were analyzed on the Beckman Coulter
automatic sequencer in a 17-minute run, and all the base
changes of codons 12 and 13 were detected. These results
indicated that the direction of the primer do not play an
important role in detecting the base changes at a given
codon. We then used different-sized primers of the same
direction (sense strand) to recognize the first and the sec-
ond base changes separately, and all the base changes of
codons 12 and 13 were detected. We also used degenerate
probes (containing a degenerate base at the last base of
the probe to detect the second base change of codon 12 or
13) and they also worked well (data not shown). After this
preliminary study using four probes to detect codon 12
and codon 13 mutations, we added five more probes to
detect codon 61 and codon 146 mutations. This collec-
tion of probes defines our multiplex PCR and primer
extension method for codons 12, 13, 61, and 146.
We then used our multiplex PCR and primer extension
method to assay 228 cases of colorectal cancer. The results
showed that 83 cases have K-RAS  mutations in the
hotspots that we screened. Of the 83 mutant cases, there
were 58 cases of codon 12 mutations including 7 cases of
GGT→TGT, 3 cases of GGT→AGT, 18 cases of GGT-GTT,
29 cases of GGT→GAT and 1 case of GGT→GCT. There
are 21 cases of codon 13 mutations, including 1 case of
GGC→CGC and 20 cases of GGC→GAC. There was one
example showing a mutation of codon 61 (CAA→CAT),
and there were three cases of codon 146 mutations, all of
which were of the GCA→ACA mutation. The mutations in
all of these cases were heterozygous.
Sensitivity of the K-RAS mutation assay
We next determined the minimal amount of DNA
required for reliable mutation detection. We diluted DNA
samples harbouring codon 12 and 13 mutations, and ana-
lyzed the samples as described above. For each of the
mutations, we found that 10 ng of DNA was enough for
the multiplex PCR reaction. We subsequently determined
the lowest concentration of mutant DNA in a background
of normal DNA needed for mutation detection. We mixed
tumor DNA (heterozygous for the mutation at codons 12
and 13) with control DNA in different ratios (1:3, 1:13
and 1:20) (Fig. 1). The result showed that this method can
detect K-RAS mutations in a DNA mixture containing as
little as 5% mutant DNA.
Mutational analysis of K-RAS gene in colorectal cancers
We used direct sequencing to analyze the mutations of the
K-RAS  gene in the coding and intron-exon junction
regions of exons 2, 3, and 4. As expected, the results
showed hotspot K-RAS mutation in 83 of the 228 cases.BMC Cancer 2009, 9:179 http://www.biomedcentral.com/1471-2407/9/179
Page 3 of 7
(page number not for citation purposes)
The results of sequencing analysis were identical to the
results of multiplex PCR with primer extension analysis.
There were no compound heterozygous mutations or
homozygous mutations in any of these cases, and the
mutational frequencies of codons 12, 13, 61, and 146
were 25.4%, 9.2%, 0.4% and 1.3%, respectively. We did
not find any other mutations, such as mutations at codons
10, 11, 15, 18, 19 or 22. We can therefore conclude that
our method was very accurate in profiling the mutations
in colorectal cancers, and will detect the majority, if not
all, of the K-RAS mutations commonly seen in cancer.
Correlation between K-RAS mutations and 
clinicopathological data in colorectal cancers
We compared the clinicopathological data of colorectal
cancer patients with the mutational status of K-RAS in
their cancerous tissues. The univariate analysis revealed
that there is a significant association between K-RAS
mutation at codon 12 of exon 2 and poor 5-year survival.
This mutation also serves as a good indicator of lymph
node involvement in this disease (Table 1). Furthermore,
K-RAS mutation at codon 13 of exon 2 correlates with the
size of the tumor (>3 cm, p = 0.03). In the multivariate
analysis which incorporated independent prognostic fac-
tors of tumor size, histologic grade, and lymph node
metastasis, we found that K-RAS mutations at codon 12
and 13 of exon 2 were both significant with regard to over-
all survival (p = 0.002 and 0.025) (Table 2). Lymph node
involvement also correlates significantly with overall sur-
vival (p = 0.001). No association was observed between
codon 61 and 146 and clinicopathological features.
Discussion and Conclusion
K-RAS mutations are common in human cancers and play
a very important role in various processes of cancer devel-
opment, including cancer initiation, metastasis, prognosis
and response for treatment [1-7,10,11,30-32]. Therefore,
mutation detection of K-RAS is of clinical importance in
cancer studies. In this study, we present a simple assay to
detect  K-RAS  mutations in colorectal cancer. Several
methods can be used to detect K-RAS mutations, includ-
ing PCR and direct sequencing, PCR-RFLP and direct
Determining the sensitivity of multiplex PCR and primer extension analysis of K-RAS mutation by serial dilution of the samples Figure 1
Determining the sensitivity of multiplex PCR and primer extension analysis of K-RAS mutation by serial dilu-
tion of the samples. Upper (a), middle (b) and lower (c) panels are 1: 3, 1: 13 and 1: 20 dilution, respectively.BMC Cancer 2009, 9:179 http://www.biomedcentral.com/1471-2407/9/179
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sequencing, PCR-SSCP and direct sequencing, PCR and
probe hybridization, and allele-specific competitive
blocker PCR [19-26,33,34]. These methods are laborious
because the mutation hotspots in exons 2, 3 and 4 have to
be screened separately. Furthermore, the common muta-
tions seen at codons 12, 13, 61 and 146 are not the result
of any single nucleotide change; instead, every base at
these codons has 3 or 4 types of base changes. It is there-
fore difficult to use the above-mentioned methods to pre-
cisely detect all the base changes without using direct
sequencing or hybridization. Although the probe hybrid-
ization method requires no direct sequencing, it requires
several probes to accurately determine base changes. With
our method, the detection of base changes in three key
exons of K-RAS can be combined into one assay, which
allows a sample to be screened for all K-RAS mutation
hotspots simultaneously. Because the technique is a
sequencing-based approach, additional sequencing is not
necessary. Meanwhile, the advantage of using primer
extension over hybridization with allele-specific oligonu-
cleotide probes to distinguish sequence variants is based
on the high accuracy of the nucleotide incorporation reac-
tion catalyzed by a DNA polymerase compared with the
caveats of hybridization. These caveats include differences
in thermal stability between mismatched and perfectly
matched hybrids formed with the allele-specific oligonu-
cleotide probes. Current products of the thermostable
enzymes used in primer extension reaction have very low
error rates and have increased efficiency and specificity for
ddNTPs [35]. These characteristics provide negligible
primer misincorporation and excellent discrimination
between wild, heterozygous and homozygous genotypes.
Additionally, the same reaction conditions can be used to
detect any variable nucleotide regardless of the nucleotide
Table 1: Correlation between clinicopathological features and K-RAS mutation of codon 12 1st base and codon 13 2nd base
mutation of codon 12 1st base mutation of codon 13 2nd base
no yes total p-value no yes total p-value
Tumor size <= 3 cm 55 5 57 1 56 1 57 0.03
>3 cm 160 8 168 149 19 168
Grade Well 4 0 4 0.749 4 0 4 0.416
Moderate 171 9 180 161 19 180
Poor 10 1 11 11 0 11
Lymph node metastasis - 107 2 109 0.048 101 8 109 0.621
+ 88 8 96 87 9 96
Stage I, II 76 0 76 0.121 70 6 76 0.782
III, IV 76 4 80 72 8 80
Survival <= 5 years 114 9 123 0.023 109 14 123 0.162
>5 years 104 1 105 99 6 105
p-value by Chi-square Test or Fisher's Exact Test when appropriated
Table 2: Multivariate analysis (Cox regression) of independent prognostic factors in patients with colorectal cancer
Harzard Ratio 95% CI p-value
Mutation Codon 12 1st base - 1.0 1.14 to 4.71 0.002
+2 . 3
Codon 13 2nd base - 1.0 1.09 to 3.58 0.025
+2 . 0
Tumor size <= 3 cm 1.0 0.60 to 1.48 0.803
>3 cm 0.9
Grade well 1.0 0.26 to 2.69 0.762
moderate/poor 0.8
Lymph node metastasis - 1.0 1.33 to 2.86 0.001
+2 . 0BMC Cancer 2009, 9:179 http://www.biomedcentral.com/1471-2407/9/179
Page 5 of 7
(page number not for citation purposes)
sequence flanking the variable site. Another advantage of
the primer extension reaction is its multiplexing capabil-
ity, with several mutations being detected in a single reac-
tion tube. Although multiplex PCR-SSCP- or PCR-ARMS-
based methods can also simultaneously detect several
mutations, PCR-SSCP require further confirmation by
direct sequencing, and using PCR-ARMS to detect all the
changes at codons 12, 13, 61 and 146 require more prim-
ers than are possible for one reaction tube. Our multiplex
primer extension methods can detect more than 40 types
of changes at these 4 codons. Compared with direct
sequencing, primer extension reaction assays are faster
because automated fluorescent capillary electrophoresis
of the products requires only 25 minutes in comparison
with more than one hour for capillary electrophoresis
require for standard sequencing. However, we should
point out that our proposed method can only detect K-
RAS mutations in a DNA mixture containing at least 5%
mutant DNA. Moreover, our method can not detect K-RAS
mutations occurred outside the codons that we targeted
although direct sequencing we performed did not find
any either. In the past, primer extension-based methods
were used for detecting a single base change across several
conditions, and they have rarely been used to detect the
three base changes at a given codon [36-40]. In this study,
we extend the application to detect all the base changes at
a given codon of K-RAS gene simultaneously and estab-
lished it as a simple and fast way to screen K-RAS gene.
Our results indicated a strong association between K-RAS
mutation in exon 2 and clinical outcome in terms of sur-
vival, lymph node involvement, and tumor size. Mutated
exon 2 of K-RAS, thus represents a molecular lesion in the
development of more aggressive disease. The effectiveness
of cetuximab in colorectal cancer is strongly associated
with K-RAS  mutation status [12]. The method that we
demonstrated in this report provides a simple, fast, and
reliable way to identify K-RAS mutation for the purpose of
clinical evaluation in colorectal cancer. Meanwhile, the
principle of the method can also be used to detect H-RAS
and N-RAS mutations, or to detect the mutation at a given
codon in other genes in colorectal and other cancers
Methods
Samples
Resected primary colorectal cancers were obtained from
228 patients in Changhua Christian Hospital. All the cases
were adenocarcinomas and were classified as "poorly-dif-
ferentiated" to "well-differentiated". All patients were
staged according to the 2002 American Joint Committee
on Cancer staging system [41]. The tumor specimens were
frozen immediately after surgical resection and stored in
liquid nitrogen until DNA was extracted. The age of the
patients ranged from 36–72 years with a mean of 49 years.
This study was approved by the Institute Review Board of
Changhua Christian Hospital.
DNA extraction, PCR and direct sequencing of the K-RAS 
gene
DNA extraction was performed as previously described
[33]. Three pairs of primers were used to amplify the exon-
intron junctions and coding regions of exons 2, 3, and 4
of the K-RAS gene (see Additional file 1). The PCR was
performed with a denaturing step at 94°C for 5 min, then
30 sec at 94°C, 30 sec at 56°C, and 1 min at 72°C for 35
cycles, followed by a final 5 min at 72°C. The PCR prod-
ucts were visualized on a 2.5% agarose gel. These PCR
products were then subjected to direct sequencing using
the same primers, and all mutations were confirmed by
sequences originating from both the upstream and down-
stream primers. Direct sequencing was performed on a
Beckman Coulter CEQ 8000 Series Genetic Analysis Sys-
tem (Beckman Coulter Inc., Fullerton, CA, USA) accord-
ing to manufacturer instructions.
Multiplex PCR and primer extension analysis of mutations 
in K-RAS codons 12, 13, 61 and 146
Multiplex PCR was used to amplify exons 2, 3 and 4 of K-
RAS gene in a single tube. The primers used for the multi-
plex PCR were identical to those used for the direct
sequencing analysis. After multiplex PCR amplification,
the PCR products were purified to remove the remaining
primers and unincorporated deoxynucleotide triphos-
phates, using the PCR-M™ Clean Up System (Viogene-
biotek Co., Sunnyvale, CA, USA) or a simple treatment
with exonuclease I and shrimp alkaline phosphatase. After
removing the primers, the products were subjected to
primer extension analysis. The primers ranged from 20–
65 bases, and most probed the sense strand (see Addi-
tional file 2). The exception was when there were adjacent
mutations; in this case both sense and antisense strand
primers were used. Degenerate bases were used in the
primers to identify adjacent mutations. Various concen-
trations of probe for either codon 12, 13, 61 or 146, were
added to the tube containing purified PCR products, as
well as 4 μl of SNPStart Master Mix (Beckman Coulter
Inc., Fullerton, CA, USA) containing Taq DNA polymerase
and fluorescently labelled ddNTPs. Each 10-μl mixture
was subjected to 30 single-base extension cycles consisting
of a denaturation step at 90°C for 10 sec, and primer
annealing and extension at 55°C for 20 sec. After cycle
extension, unincorporated fluorescent ddNTPs were incu-
bated with 0.25 μl of shrimp alkaline phosphatase (SAP)
(United States Biochemical Co., Cleveland, USA), 1.3 μl
SAP buffer, and 1.45 μl ddH2O at 37°C for 30 min, fol-
lowed by enzyme deactivation at 65°C for 15 min.
The primer extension reaction products were resolved by
automated capillary electrophoresis on a capillary electro-
phoresis platform. Briefly, 38.75 μl of sample loading
solution and 0.25 μl of Size Standard 80 (Beckman Coul-
ter Inc., Fullerton, CA, USA) were added to 1 μl of primerBMC Cancer 2009, 9:179 http://www.biomedcentral.com/1471-2407/9/179
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extension products. The fluorescently tagged extended
products in the mixture were electrophoretically separated
across a 36-cm capillary containing POP-4 for 17 min and
analyzed using GeneScan application software (Beckman
Coulter Inc., Fullerton, CA, USA)
Statistics
Comparison between clinicopathological features and
status of K-RAS mutation in colorectal cancers were ana-
lyzed by Chi-square test or Fisher's exact test. Independent
prognostic factors were analyzed by the Cox proportional
harzards regression model. Variables in the model
included tumor size, histologic grade, and lymph node
metastasis. A P value of less than 0.05 was considered sta-
tistically significant.
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